At the news
? NEUTRALIMPACT 2/10 8-K filed Jul 9, 2026 at 17:10 ET
Travere Therapeutics announced the planned retirement of CAO Sandra Calvin after the filing of the 2026 10-K (expected February 2027), with VP Controller John Torell set to succeed her. The transition is orderly with an internal replacement already named, making this a routine personnel event with no material financial impact.
- CAO Sandra Calvin intends to retire following the filing of the 2026 annual report (expected February 2027).
- John Torell, CFA, CPA, currently VP Controller, is expected to succeed her as CAO and PAO.
- Torell joined Travere in 2021 and has overseen accounting operations, financial reporting, SEC reporting, and internal controls.
- The Board is expected to appoint Torell in advance of the Retirement Date to ensure an orderly transition.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access